MedTrace Logo

Oropharynx (OPX) Biomarker Trial

NCT06356272 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 560

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.

Conditions

  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Metastatic Oropharyngeal Squamous Cell Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Head and Neck Carcinoma
  • Head and Neck Neoplasm
  • Salivary Gland Neoplasms
  • Thyroid Gland Neoplasm

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

Principal Investigators

  • Kathryn M. Van Abel, MD · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2029-11-30
Completion
2029-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06356272 on ClinicalTrials.gov